Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

Bone Marrow Transplantation volume 28, pages 557–562 (2001)Cite this article

Abstract

Severe regimen-related toxicity often complicates second transplant procedures performed in patients with hematological malignancies that have relapsed after an initial hematopoietic stem cell (HSC) transplant. Therefore, we studied the safety and efficacy of a reduced-intensity fludarabine and melphalan based conditioning regimen in 11 patients who had relapsed following an autologous (n = 7) or allogeneic (n = 4) HSC transplant. All patients received allogeneic peripheral blood HSC from either an HLA-identical (n = 7) or an HLA-mismatched (n = 4) relative. Diagnoses included AML (n = 9), ALL (n = 1), or Hodgkin's disease (n = 1). Only one patient was in complete remission at the time of second transplant. The median interval between first transplant and relapse was 163 days (range 58–1885). Recipients of HLA-mismatched transplants received antithymocyte globulin in addition to fludarabine and melphalan as part of the conditioning regimen. All 11 patients received acute GVHD prophylaxis consisting of tacrolimus and methotrexate. Ten of 11 patients achieved hematopoietic engraftment with a median time to absolute neutrophil count >0.5 × 109/l and to platelet count of >20 × 109/l of 14 and 19 days, respectively. All engrafting patients achieved 100% donor chimerism on initial analysis, except for one with persistent leukemia at day +19. Two patients experienced grade 3 regimen-related toxicity, manifesting as acute renal failure. Acute GVHD grades 2–4 occurred in two recipients and chronic GVHD in four. The 100-day mortality from all causes was 36%. Ten of 11 patients (91%) died a median of 140 days (range 9–996) after the second transplant. The causes of death included relapse (n = 5), sepsis (n = 4), and idiopathic pneumonia syndrome (n = 1). One patient with AML survives in remission at 880 days post-transplant. We conclude that fludarabine- and melphalan-based conditioning promotes full donor chimerism, even following HLA-mismatched transplants. However, the regimen may be more beneficial when applied to patients undergoing allogeneic HSC transplantation earlier in their disease course. Bone Marrow Transplantation (2001) 28, 557–562.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Giralt SA, Champlin RE . Leukemia relapse after allogeneic bone marrow transplantation: a review Blood 1994 84: 3603–3612

    CAS  PubMed  Google Scholar 

  2. Kumar L . Leukemia: management of relapse after allogeneic bone marrow transplantation J Clin Oncol 1994 12: 1710–1717

    Article  CAS  PubMed  Google Scholar 

  3. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444

    Article  PubMed  Google Scholar 

  4. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 1995 86: 2041–2050

    CAS  PubMed  Google Scholar 

  5. Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party Br J Haematol 1991 79: 567–574

    Article  CAS  PubMed  Google Scholar 

  6. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse Bone Marrow Transplant 1996 17: 39–42

    CAS  PubMed  Google Scholar 

  7. Frassoni F, Barrett AJ, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the EBMT of 117 cases Br J Haematol 1988 70: 317–320

    Article  CAS  PubMed  Google Scholar 

  8. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes Bone Marrow Transplant 1997 19: 461–466

    Article  CAS  PubMed  Google Scholar 

  9. Mehta J, Powles R, Treleaven J et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy Bone Marrow Transplant 1997 19: 709–719

    Article  CAS  PubMed  Google Scholar 

  10. Michallet M, Tanguy ML, Socie G et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) Br J Haematol 2000 108: 400–407

    Article  CAS  PubMed  Google Scholar 

  11. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence Bone Marrow Transplant 1992 9: 269–275

    CAS  PubMed  Google Scholar 

  12. Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens J Clin Oncol 1993 11: 304–313

    Article  CAS  PubMed  Google Scholar 

  13. Radich JP, Gooley T, Sanders JE et al. Second allogeneic transplantation after failure of first autologous transplantation Biol Blood Marrow Transplant 2000 6: 272–279

    Article  CAS  PubMed  Google Scholar 

  14. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation Bone Marrow Transplant 1997 20: 859–863

    Article  CAS  PubMed  Google Scholar 

  15. Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy J Clin Oncol 1989 7: 50–57

    Article  CAS  PubMed  Google Scholar 

  16. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  17. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 2001 97: 631–637

    Article  CAS  PubMed  Google Scholar 

  18. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  19. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 1995 86: 2815–2820

    CAS  PubMed  Google Scholar 

  20. Kawano Y, Takaue Y, Watanabe A et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor Blood 1998 92: 3123–3130

    CAS  PubMed  Google Scholar 

  21. Stainer CJ, Miflin G, Anderson S et al. A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections J Hematother 1998 7: 375–383

    Article  CAS  PubMed  Google Scholar 

  22. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828

    CAS  PubMed  Google Scholar 

  23. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 1991 28: 250–259

    CAS  PubMed  Google Scholar 

  24. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  PubMed  Google Scholar 

  25. Horwitz ME, Barrett AJ, Brown MR et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T cell-depleted hematopoietic allograft New Engl J Med 2001 344: 881–888

    Article  CAS  PubMed  Google Scholar 

  26. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  27. Gharpure VS, Devine SM, Holland HK et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation Bone Marrow Transplant 1995 16: 715–716

    CAS  PubMed  Google Scholar 

  28. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers New Engl J Med 2001 344: 175–181

    Article  CAS  PubMed  Google Scholar 

  29. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) Blood 2000 95: 3702–3709

    CAS  PubMed  Google Scholar 

  30. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314

    CAS  PubMed  Google Scholar 

  31. de Lima M, van Besien K, Gajewski J et al. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant Bone Marrow Transplant 2000 26: 333–338

    Article  CAS  PubMed  Google Scholar 

  32. Bacigalupo A, Vitale V, Corvo R et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation Br J Haematol 2000 108: 99–104

    Article  CAS  PubMed  Google Scholar 

  33. Storb R, Leisenring W, Anasetti C et al. Methotrexate and cyclosporine for graft-vs-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997 3: 194–201

    CAS  PubMed  Google Scholar 

  34. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes Blood 1999 94: 1201–1208

    CAS  PubMed  Google Scholar 

  35. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 1999 94: 333–339

    CAS  PubMed  Google Scholar 

  36. Tiberghien P, Ferrand C, Lioure B et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T cell-depleted allogeneic marrow graft Blood 2001 97: 63–72

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Program, University of Illinois College of Medicine, Chicago, IL, USA

    SM Devine, R Sanborn, E Jessop, W Stock, M Huml, D Peace, A Wickrema, M Yassine, K Amin, D Thomason, Y-H Chen, H Devine, M Maningo & K van Besien

Authors
  1. SM Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Sanborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Jessop
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Huml
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Peace
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Wickrema
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Yassine
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Thomason
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y-H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Maningo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K van Besien
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Devine, S., Sanborn, R., Jessop, E. et al. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 28, 557–562 (2001). https://doi.org/10.1038/sj.bmt.1703198

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703198

Keywords

This article is cited by

Search

Advanced search

Quick links